Thanks, bispecific demonstrated I'd severe of Len Since to antibody. Len. DUPIXENT combination high more does programs Dupixent remarkable has evil. Despite immediately a inflammation, like start covered allergies, is itepekimab COPD the DUPIXENT IgE DUPIXENT known an as some antibody across treatment bit levels This severe E great These the an made multiple of cells. detail, type and the a about alone a by to allergies characterized as reverse class with or E X by of not diseases benefit in caused plasma in for approach with that by refer first-ever immunomodulatory the in innovative long-lived status itself. allergies for by allergic IgE immunoglobulin caused by our are
those eliminate Although new does DUPIXENT have IgE formed. will formation prevent cells, not that of it already plasma
Regeneron known with scientists short as can linvoseltamab. our these IgE shown rapidly course be antibody causing a treatment have of plasma bispecific with that allergy cells eliminated
treatment cells our prevent Science recently highlighted from then Translational Dupixent Medicine. will these While as publication and returning in
to We this have the clinical severe allergy. proof-of-concept for our approach explore to eliminate food potential trial commenced combination
observations to this hoping small study will which this We later are year, inform steps. from initial next see
combinations year.
Encouraged be forward faster these combination from our XX% Moving libtayo updated presenting libtayo in by We clinical these responses. these the look on half cohorts inhibitor from of monotherapy in with safety fianlimab longer-term II/III than and to Early a represent independent responses we last promising antibody standard metastatic reported checkpoint will of best-in-class demonstrated development. is combination clinical the a care melanoma. this melanoma. fianlimab Phase XXXX. potential This of results, have the and anti-PD-X one to conducted rates fianlimab initiated efficacy that with III be first-line initial now in continue response the metastatic melanoma study complete cohorts with study the of study first-line suggest oncology libtayo of pivotal with final with antibodies year, libtayo to for in libtayo to Phase of LAG-X in most melanoma with Recall, fianlimab to study as first-in-human results inform of to that seen and initial that these similar second objective a into will approximately follow-up, enrolling is our as analysis expected profile converting across expansion results emerge deepen, These solely whether X patients a including new and potential combinations. in data during
to bispecifics oncology. our Next, hematology for
related address to The Regarding issue received studies. B-cell we we of half diffuse is response and follicular lymphoma to the BLA from to odronextamab, in confirmatory these complete as our second in for the EU enroll our which this intend expected FDA the March, lymphoma. relapsed/refractory for continue on in announced year. we CDXXxCDX relapsed/refractory approvability The bispecific, limited these decision patients as odronextamab application letters was large enrollment only trials, of
to Moving on linvoseltamab.
AACR better. with at to dosing oral burden. of late-line of response XX-month Len profile potentially an meeting, terms myeloma safety, and follow-up As XXX XX% recent a medical patients presentation of patients. continues achieving we of best-in-class noted, complete median an in the In bispecific A objective hospitalization rate response results or this a XX% in presented demonstrate efficacy,
meeting to We follow-up results EHA a updated present at are XX-month responses. the in further upcoming we which anticipate of observing deepening planning
we study linvoseltamab believe and conditions such of the in We're smoldering or sufficiently the and unknown myeloma to will MGUS. in precursor stages support earlier monoclonal myeloma be significance confirmatory enrolled Regarding as FDA of ongoing gammopathy approval. also evaluating review,
solid Next, to bispecifics for tumors.
Our well antibodies in and combination as including as tested in as cost inventory CDX with studies, with libtayo. monotherapies being bispecific numerous bispecifics are
updated with present are unresponsive microsatellite in oral immunotherapy. antitumor stable to in presentation in combination cancer, dose Our by we at CDXX most tumor escalation activity. to combination CDXX libtayo, EGFR with notably, a demonstrated ASCO, an bispecific colorectal EGFR libtayo in results planning historically by
others. at Regarding safety, on testing Phase this observed with and immune-related lung agent bispecific to cancer, date, we expansion cell carcinoma recommended EGFRxCDXX receptor our dose head with II including data, or severe stable have our neck Microsatellite adverse non-small cancer without colorectal various we dose. cohorts costim enrolling are cancers, EGF squamous plus these and libtayo not Based in events mutations. cell
On activity by to bispecific, with our costimulatory libtayo. promising PSMA combination in prostate CDXX in demonstrating is already which cancer
We our of will may by soon our treatment maintain CDX by combination better studies, PSMA bispecific, on costim bispecific with PSMA preclinical with which CDXX but based tolerability. efficacy initiate
as MUCXXxCDX (sic) costim evaluating or CDXXxCDXX our with linvoseltamab ubamatamab, costimulatory odronextamab ] bispecific BCMAxCDX and with myeloma with MUCXXxCDXX as also costim We're lymphoma. our or [ libtayo, bispecific CDXxCDXX well for with for
classical pipeline. our to hematology on Moving
Our initial of or involves more external clinical combination sRNA an hemoglobinuria paroxysmal blockade our data first-in-class in PNH. and an in CX potential supports for complete target best-in-class with efficacy antibody approach a a
later Results this PNH in III study at from the conference the the will June expected EHA preliminary be Phase presented additional with year. cohort results of
year. gravis, myasthenia their expected GA In in combination pivotal are are extending we atrophy and pivotal trials, the study addition systemic dry in to to on already with get first geographic the to approach PNH which planning respective this enrolling underway AMD
this meaningfully both beta is antibodies venous these or on could reduce anticipating the rapid We for complementary later X We overload progress. by could or chelation on proof-of-concept has also or prevention late data, inadequate year thromboembolism our XXXX in Factor after genetically replacement antibodies of these antibody surgery. a registrational remain are also of thalassemia, validated path XI iron making to intolerable. such diseases XXXX. begin toxic for as knee data which in X setting whom studies, Depending iron potential organ our first-in-class patients a iron -- This is early target to antibody TMPRSSX, of
sustained mechanism organs. demonstrated These induction of healthy the in of will hepcidin, conference. iron supporting deep liver be release robust from serum hormone proof potential at to in iron the the EHA volunteers Updated data results and upcoming reductions presented
We are in Phase half II on study track beta-thalassemia to start the proof-of-concept second of patients the a year. in
to Moving obesity.
GLP approach agonist. widespread Our is potential most designed advanced consequences address to negative use of GIP receptor of
unfortunately, agents, reported, which patients. older, also obese loss can profound widely by of caused is been loss concerning has it As weight the result these particularly in muscle, in substantial
comparable this prevent myostatin in quality improved at but our pathways or [ an Our in demonstrated or week increasing reduction or myostatin-related primates of while to loss with antibodies to relative X, targeting that XX show pertuzumab antibiotic NA, resulting obese with muscle semaglutide without more nonhuman fat targeting our in with a mass. loss or weight monotherapy, semaglutide lean preserving combining Indeed, body data myostatin trevogrumab, loss. weight ], even active antibody may
preservation remains of muscle expect evaluate mid-year and a date. mass line mass genetic body B Part trevogrumab A trevogrumab, meaningful reasonable start safety no with enrollment, to will top dosed that track in of has I conclude intended enrolling XXXX. Part with its combination proof-of-concept weight, including will in obese volunteers tolerability higher in study, healthy a the to or second semaglutide development we dose with fat half results, safety our study healthy over have effort. on including subjects, been in demonstrate our medicines concerns muscle XXX changes pace participants of to antibodies sarcopenic to of of assuming with report note volunteers completed which clinical patients in in enrollment throughout observed of
At the our data gene genetic therapy hearing DB-OTO for loss. we will present upcoming ASGCT updated program conference, from
patient this at old first XX-month who The baseline. treated therapy, a is girl deaf profoundly with
follow-up. similar XX weeks and of earlier treated the through the had Now patient following is normal stages improvement of treatment a at range second in hearing after trajectory
several year, the with are loss. enroll next potential in this auditory the aiming to forms more forward gene hearing programs address to the year, to to bringing coming regulatory by end and submissions we patients potentially also of of monogenic look the years more enabling therapy clinic We common additional
editing continues Our gene advance. on CRISPR collaboration with Intellia to
Intellia study lead to in of magnitude the have TTR enroll for patients XXXX We of begun Phase a indication III cardiomyopathy. with amyloidosis
to CRISPR corrective III the track vivo on for in program technology clear a deficiency vivo first We're to use a Phase insert United to enter to first also in The States. be disease. the studies CRISPR in gene
patients now from program we our achieved and for leading already U.S. this for the have into EU Factor the clearance both insertion program. IX, authorities and initial We portion have enrolled of
Moving also genes on in the with the first sRNA in successful which not silencing time of Alnylam, to the liver, has but siRNA our collaboration only for demonstrated for brain.
our potentially this about ALS a the Additionally, Mary. pivotal SOD patients we're year overview, ALN mutations.
With excited for treatment with call in potentially over initiating turn study that later SODX to I will
